Tag: biosimilars market demand

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Biosimilars Market Value Growth And Long-Term Outlook

The biosimilars market has experienced significant expansion recently. It is projected to expand from $21.85 billion in 2025 to $25.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.9%. Historically, this growth has been driven by factors such as the increasing incidence of chronic and autoimmune diseases, the substantial expense of original biologic drugs, a rising need for affordable treatment options, continuous innovation in biopharmaceutical research and development, and the improvement of healthcare infrastructure in developing economies.

The biosimilars market size is anticipated to experience significant expansion over the next few years. It is projected to increase to $48.52 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.4%. This growth during the forecast period is primarily driven by factors such as the expiration of patents for major biologics, the rising use of biosimilars in oncology and autoimmune therapies, favorable government incentives and policies, the scaling of manufacturing capabilities in the Asia-Pacific region, and an increase in partnerships between biopharma companies and contract manufacturing organizations. Noteworthy trends for this period encompass personalized biosimilar development, the manufacturing of cost-effective biologics, regulatory alignment and adherence, the expansion of biosimilar markets into emerging regions, and strategic collaborations and alliances.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Biosimilars Market Growth Drivers: What’s Behind The Acceleration?

Rising healthcare expenditures are anticipated to drive the expansion of the biosimilars market moving forward. These expenditures represent the aggregate spending on medical goods and services within a particular population or healthcare system. The biosimilars market aids in decreasing healthcare spending by presenting more affordable options than expensive biologic drugs, thus reducing treatment costs for both patients and healthcare systems. For instance, in March 2024, according to the Health Foundation, a UK-based independent charity and think tank, the overall health expenditures in England for the last confirmed spending year, 2022/23, amounted to £182 billion ($196.78 billion). While planned health spending is projected to reach £192 billion ($207.59 billion) in 2024/25, inflation is expected to limit the real-term increase to merely 0.6% compared to the 2023/24 fiscal year. Hence, growing healthcare expenditures are a primary impetus for the biosimilars market’s growth.

Biosimilars Market Segment Analysis: What Are The Core Market Categories?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

Biosimilars Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies within the biosimilars market prioritize the creation of innovative products to secure a competitive advantage. FYLNETRA serves as a leukocyte growth factor, designed to reduce the occurrence of infections, specifically febrile neutropenia, in patients with non-myeloid cancers who are undergoing myelosuppressive anti-cancer drug treatments that carry a high risk of febrile neutropenia. As an illustration, in May 2023, Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the US, initiated the commercial release of FYLNETRA (pegfilgrastim-pbbk), a biosimilar that references Neulasta and is available in a pre-filled single-dose syringe. FYLNETRA is employed for managing neutropenia (a condition characterized by low levels of neutrophils, a kind of white blood cell crucial for fighting infection), a common side effect for individuals receiving chemotherapy.

Biosimilars Market Top Companies Driving Competitive Growth

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

View The Full Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Biosimilars Market Geographic Distribution And Regional Opportunities

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Biosimilars Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The biosimilars sector has experienced swift expansion in recent years. Projections indicate an increase from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. Several factors have driven this historical growth, including the escalating incidence of chronic and autoimmune conditions, the substantial expense of reference biologics, a heightened need for affordable treatment options, progress in biopharmaceutical research and development, and the strengthening of healthcare systems within developing countries.

The biosimilars market is projected to experience significant growth over the coming years, with its value anticipated to reach $48.52 billion by 2030, expanding at a compound annual growth rate (CAGR) of 17.4%. This forecasted expansion is driven by the expiration of patents for major biologic drugs, heightened utilization of biosimilars in oncology and autoimmune treatments, favorable government policies and incentives, enhanced production capabilities in the Asia-Pacific region, and increased collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends shaping this period include the emergence of tailored biosimilar development, more cost-efficient biologic manufacturing, progress in regulatory alignment and compliance, growth of biosimilar markets in developing regions, and a rise in strategic alliances and joint ventures.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Biosimilars Market Development Factors: Which Trends Are Supporting Demand?

The rising costs of healthcare are anticipated to drive the expansion of the biosimilars market in the coming period. Healthcare expenditures encompass the overall amount spent on medical goods and services within a specific population or system. By providing more affordable options compared to costly biologic drugs, the biosimilar sector helps cut treatment expenses for patients and healthcare systems, thereby reducing overall healthcare spending. For example, in March 2024, the Health Foundation, an independent UK charity and think tank, reported that total health spending in England reached £182 billion ($196.78 billion) in 2022/23, the most recent year with confirmed data. Although planned health expenditures are expected to climb to £192 billion ($207.59 billion) in 2024/25, inflation will limit the real-term increase to just 0.6% relative to the 2023/24 fiscal year. Consequently, the growth of the biosimilars market is being fueled by increasing healthcare expenditures.

Biosimilars Market Segments: Where Are The Largest Growth Opportunities?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

Biosimilars Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the biosimilars industry are concentrating on developing cutting-edge products to secure a competitive advantage within the sector. FYLNETRA, a leukocyte growth factor, is designed to reduce the occurrence of infections, particularly those presenting as febrile neutropenia, in patients with non-myeloid cancers who are undergoing myelosuppressive chemotherapy regimens linked to a notable risk of febrile neutropenia. A notable example occurred in May 2023, when Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the United States, introduced FYLNETRA (pegfilgrastim-pbbk) to the market, a biosimilar referencing Neulasta, delivered in a prefilled single-dose syringe. This therapy addresses neutropenia—a condition characterized by low levels of neutrophils, the white blood cells essential for fighting infections—frequently experienced by individuals during chemotherapy.

Biosimilars Market Major Participants And Competitive Dynamics

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Biosimilars Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Biosimilars Market Become By 2030 Compared To 2026?

The biosimilars market size has experienced considerable growth recently. This market is set to expand from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. Historically, this expansion has been attributed to several factors including the increasing occurrence of chronic and autoimmune diseases, the significant cost associated with originator biologics, a rising preference for more economical therapies, breakthroughs in biopharmaceutical research and development, and the development of healthcare infrastructure in emerging economies.

The biosimilars market size is projected to undergo substantial growth over the next few years, with expectations to reach **$48.52 billion by 2030**, expanding at a compound annual growth rate (CAGR) of **17.4%**. This anticipated growth throughout the forecast period is primarily driven by the expiration of patents for significant biologics, a rising adoption of biosimilars within oncology and autoimmune treatments, supportive government incentives and policies, an increase in manufacturing capacities across Asia-Pacific, and strengthening partnerships between biopharma companies and contract manufacturing organizations. Noteworthy trends during this same period include the advancement of personalized biosimilar development, the focus on cost-effective biologics manufacturing, efforts towards regulatory harmonization and compliance, the expansion of new markets for biosimilars, and various strategic collaborations and partnerships.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Which Significant Factors Are Encouraging Growth In The Biosimilars Market?

Rising healthcare spending is anticipated to boost the expansion of the biosimilars market in the future. Healthcare expenditures signify the cumulative outlay for medical goods and services within a specific population or system. The biosimilars market contributes to decreasing healthcare costs by providing more economical substitutes for costly biologic medications, thus reducing treatment expenses for both patients and healthcare providers. For example, in March 2024, the Health Foundation, a UK-based independent charity and think tank, reported that England’s total health expenditures hit £182 billion ($196.78 billion) in the most recently confirmed spending year, 2022/23. Although projected health spending is slated to increase to £192 billion ($207.59 billion) by 2024/25, inflationary pressures mean that the actual real-term growth will be a mere 0.6% when compared to the 2023/24 fiscal year. Consequently, the upward trend in healthcare expenditures is propelling the expansion of the biosimilars market.

What Key Segment Areas Are Included In The Biosimilars Market Assessment?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

Which Trends Are Guiding The Development Of The Biosimilars Market?

Leading companies within the biosimilars market are concentrating on developing innovative products to achieve a competitive edge. FYLNETRA functions as a leukocyte growth factor, prescribed to lessen the occurrence of infection, as shown by febrile neutropenia, in individuals with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs linked to a clinically significant incidence of febrile neutropenia. As an illustration, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, initiated the commercial release of FYLNETRA (pegfilgrastim-pbbk), a biosimilar that references Neulasta, presented in a pre-filled single-dose syringe. FYLNETRA is utilized for the treatment of neutropenia, a condition characterized by low neutrophils (a form of white blood cell crucial for fighting infection), which is commonly experienced by patients undergoing chemotherapy.

Who Are The Key Market Participants In The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Holds The Largest Share In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Biosimilars Market Projected To Reach By 2030?

The biosimilars market has demonstrated significant expansion in recent years. It is anticipated to increase from $21.85 billion in 2025 to $25.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historic period is largely attributable to the rising prevalence of chronic and autoimmune diseases, the significant expense associated with originator biologics, an increasing demand for cost-effective therapies, continuous advancements in biopharmaceutical research and development, and the developing healthcare infrastructure in emerging economies.

The biosimilars market is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $48.52 billion, demonstrating a compound annual growth rate (CAGR) of 17.4%. This projected growth during the forecast period stems from factors such as the patent expiration of key biologics, a rise in the uptake of biosimilars for oncology and autoimmune treatments, favorable government incentives and policies, expanded manufacturing capacities in asia-pacific, and an increase in collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends observed for this period encompass the development of personalized biosimilars, more economical biologics production, improved regulatory alignment and adherence, the expansion of biosimilar markets in developing regions, and strategic alliances and partnerships.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Significant Factors Are Influencing The Biosimilars Market Expansion?

The increasing healthcare expenditures are projected to drive the expansion of the biosimilars market moving forward. Healthcare expenditures denote the overall spending on healthcare products and services within a particular population or medical system. The biosimilars market aids in diminishing healthcare expenditures by presenting more economical options compared to costly biologic drugs, thus reducing treatment costs for patients and healthcare systems. For instance, in March 2024, data from the Health Foundation, a UK-based independent charity and think tank, showed that in the most recently confirmed year for spending data, 2022/23, total health expenditures in England amounted to £182 billion ($196.78 billion). Although planned health spending is set to climb to £192 billion ($207.59 billion) by 2024/25, inflation will result in only a slight real-term increase of 0.6% compared to the 2023/24 fiscal year. Consequently, the rising healthcare expenditures are propelling the growth of the biosimilars market.

Which Segment Categories Are Included In The Biosimilars Market Segment Analysis?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Emerging Trends Are Seen In The Biosimilars Market?

Leading entities within the biosimilars sector prioritize the creation of groundbreaking products to secure a competitive advantage. FYLNETRA, a leukocyte growth factor, is prescribed to reduce the occurrence of infection, particularly febrile neutropenia, in individuals with non-myeloid malignancies who are undergoing myelosuppressive anti-cancer drug treatments that carry a clinically notable risk of febrile neutropenia. An illustrative case occurred in May 2023, when Amneal Pharmaceuticals Inc., a pharmaceutical firm based in the US, commercially introduced FYLNETRA (pegfilgrastim-pbbk), which is a biosimilar drug mirroring Neulasta, provided in a pre-filled, single-dose syringe. The drug FYLNETRA addresses neutropenia (a condition characterized by low levels of neutrophils, a crucial type of white blood cell for combating infection), a common side effect for patients undergoing chemotherapy.

Who Are The Active Companies Shaping The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Get The Full Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Where Is The Biosimilars Market Most Concentrated Geographically?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Biosimilars Market During 2026–2030?

The biosimilars market has seen rapid growth in its size in recent years. It is projected to increase from $21.85 billion in 2025 to $25.53 billion in 2026, at a compound annual growth rate (CAGR) of 16.9%. This past growth can be attributed to factors such as the rising prevalence of chronic and autoimmune diseases, the high cost of originator biologics, an increasing demand for cost-effective therapies, advancements in biopharmaceutical R&D, and the growing healthcare infrastructure in emerging economies.

The biosimilars market is projected to experience substantial expansion in the coming years. This market is forecast to reach $48.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.4%. Key drivers for this growth during the forecast period include the expiry of patents for major biologics, a rise in the use of biosimilars within oncology and autoimmune therapy, favorable government incentives and supportive policies, the broadening of manufacturing capabilities across Asia-Pacific, and an increase in collaborations between biopharmaceutical firms and contract manufacturing organizations. Significant trends anticipated in this period encompass the development of personalized biosimilars, the production of biologics in a cost-effective manner, the alignment and adherence to regulatory standards, the penetration of biosimilars into emerging markets, and strategic alliances and partnerships.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Underlying Factors Are Accelerating The Growth Of The Biosimilars Market?

Rising healthcare costs are anticipated to fuel the expansion of the biosimilars market in the future. These expenditures encompass all financial outlay for medical products and services within a specific population or healthcare framework. The biosimilars market contributes to the reduction of healthcare expenditures by providing economical alternatives to costly biologic medications, thus decreasing the financial burden of treatment for both patients and healthcare systems. As an illustration, in March 2024, data from the Health Foundation, an independent UK charity and think tank, indicated that for the most recent confirmed spending year, 2022/23, overall health expenditures in England amounted to £182 billion ($196.78 billion). Although projected health spending is expected to climb to £192 billion ($207.59 billion) by 2024/25, inflationary pressures mean that the actual increase in real terms will be a mere 0.6% when contrasted with the 2023/24 fiscal year. Consequently, the escalation of healthcare expenditures is stimulating the growth of the biosimilars market.

How Are The Various Segments Of The Biosimilars Market Categorized?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Trends Are Affecting The Expansion Of The Biosimilars Market?

Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge. FYLNETRA is a leukocyte growth factor prescribed to decrease the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. For instance, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, commercially launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, presented in a pre-filled single-dose syringe. FYLNETRA is utilized to treat neutropenia (low neutrophils, which are a type of white blood cells crucial for fighting infection), a condition commonly experienced by patients undergoing chemotherapy.

Which Major Firms Influence Developments In The Biosimilars Market?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Read the full biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Is Projected To Dominate The Biosimilars Market During The Forecast Period?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Biosimilars Market between 2026 and 2030?

The biosimilars market has demonstrated significant growth in size over recent years. Its value is predicted to increase from $21.85 billion in 2025 to $25.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.9%. The expansion observed in the past can be linked to factors such as the increasing prevalence of chronic and autoimmune diseases, the considerable expense of originator biologics, a growing demand for cost-effective therapeutic options, progress in biopharmaceutical research and development, and the evolving healthcare infrastructure in emerging economies.

The biosimilars market is projected for substantial expansion in the coming years. This market is anticipated to reach $48.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.4%. Factors driving this expansion during the forecast period include the expiry of patents for major biologics, greater integration of biosimilars into oncology and autoimmune treatments, government support through incentives and favorable policies, the enlargement of manufacturing capacities in the Asia-Pacific region, and the increasing collaborations between biopharmaceutical firms and contract manufacturing organizations. Key trends anticipated during this period encompass the development of personalized biosimilars, the production of biologics more economically, the standardization and adherence to regulations, the broadening of nascent markets for biosimilars, and the formation of strategic alliances and partnerships.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Biosimilars Market?

Elevated healthcare costs are projected to drive expansion within the biosimilars market. Healthcare expenditures encompass the collective financial outlay for medical products and services within a defined population or healthcare framework. The biosimilars market contributes to mitigating healthcare spending through the provision of more economical substitutes for costly biologic medications, consequently decreasing treatment expenses for both patients and healthcare infrastructure. As an illustration, data from March 2024, provided by the Health Foundation, a UK-based independent charity and think tank, indicates that total health spending in England for the most recent confirmed year, 2022/23, amounted to £182 billion ($196.78 billion). Although projected health spending is slated to increase to £192 billion ($207.59 billion) by 2024/25, inflationary pressures will lead to a mere 0.6% real-term growth when contrasted with the 2023/24 fiscal year. Consequently, the rise in healthcare expenditures is a key impetus behind the expansion of the biosimilars market.

How Is The Biosimilars Market Organized Into Various Segments?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones

2) By Protein Type: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

What Trends Are Driving The Growth Trajectory Of The Biosimilars Market?

Leading companies within the biosimilars market are concentrating on creating novel products to secure a competitive advantage. FYLNETRA, a leukocyte growth factor, is prescribed to reduce the occurrence of infections, particularly febrile neutropenia, in individuals with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments where febrile neutropenia is a significant clinical risk. For example, Amneal Pharmaceuticals Inc., a US pharmaceutical firm, commercially launched FYLNETRA (pegfilgrastim-pbbk) in May 2023. This biosimilar, which references Neulasta, is supplied in a pre-filled single-dose syringe. FYLNETRA addresses neutropenia, a condition characterized by low levels of neutrophils (white blood cells crucial for fighting infection), frequently observed in patients receiving chemotherapy.

Who Are The Prominent Global Companies Shaping The Biosimilars Market Landscape?

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilars market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Biosimilars Market In The Period 2029-2034?

The biosimilars market size has experienced rapid expansion in recent years. Projections indicate it will expand from $18.65 billion in 2024 to $21.85 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.2%. This historical growth is due to several factors, including a rise in cancer prevalence, robust economic growth in developing markets, increased spending on pharmaceutical research and development, higher healthcare expenditure, expanding government initiatives, a strong drug development pipeline, the economical nature of biosimilars, and an uptick in patent expirations.

The biosimilars market is projected to expand significantly in the coming years. Its valuation is anticipated to reach $41.34 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.3%. This expansion during the forecast period is propelled by several factors, including the rising incidence of cancer, a greater need for prophylaxis using granulocyte colony-stimulating factor (G-CSF), higher healthcare spending, the considerable potential of developing economies, advancements in technology, widespread adoption of biological drugs, an aging global demographic, and improved access to healthcare services. Key trends identified for the forecast timeframe encompass a strong emphasis on extensive research and development for creating impactful and novel medications, prioritizing mergers and acquisitions as a growth tactic, forging strategic alliances, boosting investments, and integrating artificial intelligence.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Strategic Drivers Are Accelerating The Biosimilars Market Expansion?

The increasing incidence of chronic illnesses such as arthritis, asthma, and cancer is expected to serve as a primary impetus for the biosimilars market. Extended work hours, insufficient physical activity, and unhealthy dietary and drinking habits contribute to the prevalence of these chronic diseases, and biosimilars are being increasingly utilized for their treatment. Biosimilars function by activating the immune system’s response against cancer cells, thereby aiding the body in their removal. A United Nations article suggests that by 2030, the percentage of global deaths attributed to chronic diseases is projected to rise to 70% of total deaths. The global burden of chronic disease is anticipated to reach approximately 60%. Thus, the escalating prevalence of chronic diseases is foreseen to boost the demand for biosimilars, consequently driving the biosimilars market.

What Is The Detailed Segment Distribution Of The Biosimilars Market?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

How Are Global Trends Impacting The Development Of The Biosimilars Market?

Leading firms within the biosimilars market prioritize the creation of innovative products to secure a competitive advantage. AMJEVITA stands as the initial U.S. biosimilar for Humira, a medication utilized by over a million individuals suffering from specific severe inflammatory conditions. For example, Amgen Inc., a US-based biotechnology firm, introduced AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), in January 2023, and it is presently accessible in the US. AMJEVITA (40 mg) can be obtained at a list price (wholesale acquisition cost) that is 55% lower than Humira’s current list price. Furthermore, AMJEVITA is additionally offered at a list price 5% beneath Humira’s present list price.

Who Are The Major Stakeholders Operating In The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2025, By The Business Research Company

Biosimilar Growth Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Biosimilars Industry Compare Between 2025 And 2029?

The biosimilars market size has experienced substantial expansion in recent years. It is projected to increase from $18.65 billion in 2024 to $21.85 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.2%. The historical growth of this market can be linked to several factors, including a rise in cancer prevalence, strong economic growth in emerging markets, increased pharmaceutical R&D expenditure, higher healthcare spending, expanding government initiatives, a robust pipeline of drugs, the lower cost of biosimilars, and an increase in patent expiration.

The biosimilars market is anticipated to experience rapid growth in the coming years, with its size projected to reach $41.34 billion by 2029, reflecting a compound annual growth rate (CAGR) of 17.3%. This expansion during the forecast period is attributable to several factors, including the increasing prevalence of cancer, a rising demand for prophylaxis using granulocyte colony-stimulating factor (G-CSF), a general increase in healthcare expenditure, the substantial potential of emerging economies, ongoing technological advances, high penetration rates of biological drugs, an aging population, and improved access to healthcare. Key trends in the forecast period include a strong focus on robust research and development (R&D) activities for developing effective and innovative drugs, an emphasis on mergers and acquisitions (M&A) as growth strategies, the establishment of strategic partnerships, increasing investments, and the integration of artificial intelligence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Which Major Market Drivers Are Shaping The Future Of The Biosimilars Market?

An increase in the occurrence of chronic conditions such as arthritis, asthma, and cancer is anticipated to be a primary driver of the biosimilars market. Contributing factors to the prevalence of chronic diseases include long working hours, limited physical activity, and unhealthy eating and drinking habits, with biosimilars increasingly utilized to treat these conditions. Biosimilars work by activating the immune system’s response against cancer cells, thereby assisting the body in eliminating them. According to a United Nations article, the proportion of global deaths attributed to chronic diseases is expected to rise to 70% of total deaths by 2030. The global burden of chronic disease is projected to reach about 60%. Therefore, the expanding prevalence of chronic diseases is foreseen to boost the demand for biosimilars, thus driving the biosimilars market.

How Is The Biosimilars Market Classified Into Different Segments?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

Which Trends Are Impacting The Biosimilars Market?

Companies operating in the biosimilars market are concentrating on developing innovative products to establish a competitive advantage. AMJEVITA holds the distinction of being the first U.S. biosimilar to Humira, a medication utilized by over a million patients managing certain serious inflammatory diseases. For example, in January 2023, Amgen Inc., a US-based biotechnology firm, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now accessible in the US. AMJEVITA (40 mg) is offered at a list price (wholesale acquisition cost) that is 55% lower than the current Humira list price. Furthermore, AMJEVITA is also available at a list price 5% below Humira’s current list price.

Who Are The Prominent Global Companies Shaping The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

What Are The Regional Market Dynamics Impacting The Biosimilars Industry?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

Browse Through More Reports Similar to the Global Biosimilars Market 2025, By The Business Research Company

Biosimilar Growth Hormone Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Biosimilars Market Be Worth By 2029?

The size of the biosimilars market has seen a quick expansion in recent years. It is anticipated to rise from $18.65 billion in 2024 to $21.85 billion in 2025, with a compound annual growth rate (CAGR) of 17.2%. Factors that contributed to the growth in the historic period include a rising incidence of cancer, robust economic development in upcoming markets, a boost in pharmaceutical research and development costs, elevated healthcare spending, increasing government schemes, a solid drug pipeline, the affordability of biosimilars, and a surge in patent expirations.

The biosimilars market is projected to experience significant expansion in the upcoming years, with a projected size of $41.34 billion in 2029, and a compound annual growth rate (CAGR) of 17.3%. Various factors contribute to this anticipated growth in the forecast period, including an uptick in cancer incidence rates, growing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), increased healthcare spending, the promising potential of emerging markets, advancements in technology, widespread use of biological drugs, an aging demographic, and improved access to healthcare. The primary trends anticipated during the forecast period are a concentration on vigorous R&D activities for creating effective and innovative pharmaceuticals, an emphasis on mergers and acquisitions for growth strategies, a focus on forming strategic alliances, increasing investment, and the incorporation of artificial intelligence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Growth-Enabling Forces Are Impacting The Biosimilars Market?

The anticipated escalation in frequency of long-suffering ailments, including arthritis, asthma, and cancer, is assumed to be a key engine propelling the growth of the biosimilars market. Contributing factors to the surge in these chronic conditions include lengthy work schedules, lack of physical exercise, and poor dietary and drinking practices, with biosimilars being increasingly utilized to manage these afflictions. Biosimilars work by prompting the immune system’s response against cancer cells thereby enabling the immune system to purge cancer cells. As per an article by the United Nations, the ratio of worldwide fatalities attributable to chronic diseases is predicted to rise to 70% of all deaths by 2030. The universal chronic disease burden is also foreseen to surge to around 60%. Consequently, this upswing in chronic illnesses is likely to stimulate demand for biosimilars, in turn, catalyzing the expansion of the biosimilars market.

How Is The Biosimilars Market Segmented Across Key Categories?

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

What Key Trends Are Driving Growth In The Biosimilars Market?

In the biosimilars market, leading companies are accentuating on the development of innovative products to maintain their competitiveness. AMJEVITA has emerged as the first U.S. biosimilar to Humira, a frequently used medicine by over a million patients struggling with certain severe inflammatory diseases. Amgen Inc., a biotechnology firm from the US, unveiled AMJEVITA (adalimumab-atto) in January 2023. It is a biosimilar to Humira (adalimumab) and is now accessible in the US. It is available at a wholesale acquisition cost, which is listed at 55% lower than the existing list price for Humira. Additionally, AMJEVITA also has a list price that is 5% less than the current Humira list price.

Who Are The Major Stakeholders Operating In The Biosimilars Market?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

How Do Regional Dynamics Influence The Biosimilars Market Performance?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Biosimilars Sector?

The dimension of the biosimilars market has expanded swiftly over the recent years. The market is projected to catapult from $18.65 billion in 2024 to $21.85 billion in 2025, with a compound annual growth rate (CAGR) of 17.2%. Factors contributing to the growth during the historic period include the rising incidence of cancer, robust economic growth in developing markets, a boost in pharmaceutical R&D spending, elevated healthcare expenses, burgeoning governmental initiatives, a sturdy pipeline of medications, inexpensive biosimilars, and an uptick in patent expirations.

The size of the biosimilars market is forecasted to witness swift expansion in the upcoming years. It is projected to escalate to “$41.34 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 17.3%. Contributing factors to this growth during the predicted period include an increased incidence of cancer, the growing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), escalation in healthcare spending, the high potential of developing economies, advancements in technology, widespread use of biological drugs, an aging populace and enhanced healthcare accessibility. The primary trends predicted for the forecast period involve enhanced emphasis on intensive R&D initiatives for generating efficacious and innovative medications, emphasis on growth strategies through mergers and acquisitions, interest in creating strategic partnerships, increased investment, and an emphasis on the use of artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

What Forces Are Driving The Growth Of The Biosimilars Market?

An upswing in chronic conditions like arthritis, asthma, and cancer is envisioned to propel the biosimilars market. Factors such as lengthy work schedules, insufficient physical exertion, and poor diet and drinking patterns contribute to the pervasiveness of these chronic diseases. To counteract this, biosimilars are utilized more frequently as a remedy for these health problems. By stimulating the body’s immune response against cancer cells, biosimilars facilitate the removal of these damaging cells. A United Nations article states that by 2030, chronic diseases would account for 70% of worldwide mortality, and the global chronic disease rate is expected to rise to approximately 60%. Consequently, the escalating prevalence of chronic diseases boosts the demand for biosimilars, further energizing the biosimilars market.

The biosimilars market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others

2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins

3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Subsegments:

1) By Monoclonal Antibodies: IgG Biosimilars, Non-IgG Biosimilars

2) By Insulin: Rapid-Acting Insulin Biosimilars, Long-Acting Insulin Biosimilars, Premixed Insulin Biosimilars

3) By Erythropoietin: Epoetin Alfa Biosimilars, Darbepoetin Alfa Biosimilars

4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

5) By Other Hormones: Growth Hormones, Hormonal Replacement Therapy Biosimilars

6) By Others: Enzyme Biosimilars, Vaccines, Other Biologics

How Are Key Trends Driving Expansion In The Biosimilars Industry?

In the biosimilars market, leading firms are concentrating on creating innovative products to establish a competitive advantage. AMJEVITA has been introduced as the inaugural U.S. biosimilar to Humira, a drug used by over a million patients dealing with specific severe inflammatory diseases. For example, in January 2023, Amgen Inc., a biotech company based in the U.S. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now accessible in the U.S. The list price (wholesale acquisition cost) of AMJEVITA (40 mg) is 55% less than the existing Humira list price. Additionally, AMJEVITA is available at a list price that is 5% less than the present Humira price.

Which Companies Currently Dominate The Competitive Landscape In The Biosimilars Industry?

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy’s Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Which Geographic Regions Are Driving Demand In The Biosimilars Market?

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2807&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model